Study finds Novo Nordisk's Ozempic diabetes drug could be produced for $5/month, raising concerns over high prices.

A study by Yale University, King's College Hospital in London, and Doctors Without Borders reveals that Novo Nordisk's diabetes drug, Ozempic, priced at almost $1,000 in the US, could be profitably produced for less than $5 a month, according to production cost estimates that include a profit margin. The study raises concerns about the high prices of top-selling diabetes treatments and drugs for weight loss.